Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00820742 |
Recruitment Status :
Withdrawn
First Posted : January 12, 2009
Last Update Posted : March 5, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Neovascular Age-related Macular Degeneration | Drug: Macugen |
Study Type : | Observational |
Actual Enrollment : | 0 participants |
Time Perspective: | Prospective |
Official Title: | The Efficacy, Safety, and Tolerability of Pegaptanib Sodium in Filipino Patients With Neovascular Age-related Macular Degeneration: A Post Marketing Surveillance Study. |
Study Start Date : | February 2008 |
Estimated Primary Completion Date : | May 2009 |
Estimated Study Completion Date : | May 2009 |

Group/Cohort | Intervention/treatment |
---|---|
Phase IV Post Marketing Surveillance Study
Open-label, observational study
|
Drug: Macugen
Intravitreous injection of Pegaptanib Sodium 3.47 mg/mL solution every 6 weeks |
- Incidence of adverse events and serious adverse events [ Time Frame: 12 months ]
- Mean change in visual acuity in the study eye at 6 months from baseline [ Time Frame: 6 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 50 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Must have at least one eye which was diagnosed with neovascular degeneration
Exclusion Criteria:
- Presence of other causes of choroidal neovascularization, including pathologic myopia (spherical equivalent of -8 diopters or more negative, or axial length of 25mm or more), ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, multifocal choroiditis

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00820742
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Director, Clinical Trial Disclosure Group, Pfizer, Inc. |
ClinicalTrials.gov Identifier: | NCT00820742 |
Other Study ID Numbers: |
A5751025 |
First Posted: | January 12, 2009 Key Record Dates |
Last Update Posted: | March 5, 2015 |
Last Verified: | March 2015 |
A5751025 |
Macular Degeneration Wet Macular Degeneration Retinal Degeneration Retinal Diseases Eye Diseases |